The G-BA Innovation Committee recommends transfer to standard care for another three completed projects in Germany

On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of booster vaccination against meningococci of serogroup C, reduction of antibiotic resistance, and dual pilot structure for diagnosis clarification in centers for rare diseases.

The “AMSeC - booster vaccination against meningococci of serogroup C: Estimation of the effects on disease burden and costs in the German healthcare system” project demonstrated that there is a decline in the protective effect against meningococcal C a few years after primary vaccination. With the help of a newly developed mathematical dynamic transmission model, a simulation was used to investigate whether a booster vaccination in adolescence with a monovaccine against meningococcal type C or a combination vaccine against meningococcal subtypes A, C, W, and Y is sensible and cost-effective. The results demonstrated the advantages of the combination vaccine and a booster vaccination at ages 13 and 14. From the perspective of the Innovation Committee, the newly developed model can support the STIKO in deciding on a booster vaccination in adolescence.

The project “REDARES – Reduction of antibiotic resistance via the guideline-based treatment of patients with uncomplicated urinary tract infections in outpatient care” examined antibiotic prescribing behavior for uncomplicated urinary tract infections. In addition, general practitioner practices received multimodal support offers, including feedback on their prescribing behavior and information on regional resistance data and information materials for patients. In an accompanying process analysis, feasibility and acceptance in practices were examined. Overall, the project demonstrated that the support offers reduced the prescription rate of second-line antibiotics and that fewer antibiotics were used overall for uncomplicated urinary tract infections.

The ”ZSE-DUO – Dual pilot structure for clarifying unclear diagnoses in centers for rare diseases” project tested a dual pilot structure at the centers - including somatic and psychiatric or psychosomatic specialists. The evaluation demonstrated that the proportion of people for whom a diagnosis could be made no later than twelve months after their first presentation at the center was significantly higher with the help of the dual guides.

The full details in German can be found here, here (AMSeC project), here (REDARES project), and here (ZSE-DUO project).

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.